Search Results for "worsen"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for worsen. Results 71 to 80 of 161 total matches.

Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia

   
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019  (Issue 1581)
; worsening of hypoglycemia has been reported. PREGNANCY AND LACTATION – Glucagon has not been associated ...
The FDA has approved glucagon nasal powder (Baqsimi – Lilly) for treatment of severe hypoglycemia in patients ≥4 years old with diabetes. Baqsimi is the first noninjectable glucagon formulation to become available in the US. Injectable glucagon emergency kits (GlucaGen Hypokit, and generic) have been available for years, but they require reconstitution of the lyophilized powder by the caregiver immediately before injection. An injectable glucagon formulation that does not require reconstitution was recently approved by the FDA (Gvoke) and is expected to become available...
Med Lett Drugs Ther. 2019 Sep 23;61(1581):148-9 |  Show IntroductionHide Introduction

Fenoldopam--A New Drug for Parenteral Treatment of Severe Hypertension

   
The Medical Letter on Drugs and Therapeutics • May 22, 1998  (Issue 1027)
). With its natriuretic/diuretic properties, fenoldopam could worsen volume depletion in some patients ...
Fenoldopam mesylte (Corlopam - Neurex), a peripheral dopamine-1 (DA1) agonist, has been approved by the FDA for parenteral use in lowering blood pressure. The manufacturer claims that, unlike other parenteral antihypertensive agents, fenoldopam not only lowers blood pressure but also maintains or improves renal function.
Med Lett Drugs Ther. 1998 May 22;40(1027):57-8 |  Show IntroductionHide Introduction

Entecavir (Baraclude) for Chronic Hepatitis B

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 2005  (Issue 1210)
with no worsening in Knodell Fibrosis Score at week 48. 2. Undetectable HBV DNA = ...
Entecavir (Baraclude - Bristol-Myers Squibb), a nucleoside analog, has been approved by the FDA for treatment of adults with active chronic hepatitis B virus (HBV) infection.
Med Lett Drugs Ther. 2005 Jun 6;47(1210):47-8 |  Show IntroductionHide Introduction

Nifurtimox (Lampit) for Chagas Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024  (Issue 1707)
, carcinogenicity, mutagenicity, worsening of neurological conditions, paresthesia, hypersensitivity, vertigo ...
The FDA has approved the nitrofuran antiprotozoal drug nifurtimox (Lampit – Bayer) for treatment of Chagas disease (American trypanosomiasis) in children who weigh ≥2.5 kg. Nifurtimox was previously available in the US only through a CDC-sponsored Investigational New Drug (IND) program.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):e123-4   doi:10.58347/tml.2024.1707h |  Show IntroductionHide Introduction

Tirzepatide (Zepbound) for Obstructive Sleep Apnea

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025  (Issue 1722)
with other weight-loss drugs; patients should be monitored for worsening depression and suicidal thoughts ...
The injectable glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide (Zepbound) has been approved by the FDA for treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. It is the first drug to be approved in the US for this indication. Zepbound is also approved for chronic weight management in adults with obesity and in those who are overweight and have at least one weightrelated comorbidity. Tirzepatide is also available as Mounjaro for treatment of type 2 diabetes.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):29-31   doi:10.58347/tml.2025.1722c |  Show IntroductionHide Introduction

Miudella – A Lower-Dose Copper IUD

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025  (Issue 5106)
worsen symptoms of the disease). CONCLUSION — Miudella, a new copper intrauterine device (IUD ...
Miudella (Sebela), a copper intrauterine device (IUD), has been approved by the FDA for prevention of pregnancy for up to 3 years. Miudella is the second copper IUD to be approved in the US; ParaGard, which contains more copper and is approved for up to 10 years of use, was approved in 1984. Four hormonal IUDs (Mirena, Liletta, Skyla, Kyleena) that release the progestin levonorgestrel are also available for pregnancy prevention (see Table 2).
Med Lett Drugs Ther. 2025 Apr 28;67(5106):1-2   doi:10.58347/tml.2025.5106a |  Show IntroductionHide Introduction

Diclofenac

   
The Medical Letter on Drugs and Therapeutics • Dec 02, 1988  (Issue 780)
thereafter, and discontinuing the drug if abnormalities persist or worsen (EG Breen et al, Gut, 27:1390 ...
Diclofenac sodium (Voltaren - Geigy), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1974, was recently introduced in the USA for treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. It is being promoted as 'The number one prescribed antiarthritic in the world.'
Med Lett Drugs Ther. 1988 Dec 2;30(780):109-11 |  Show IntroductionHide Introduction

Aspirin For Prevention Of Myocardial Infarction And Stroke

   
The Medical Letter on Drugs and Therapeutics • Aug 25, 1989  (Issue 799)
recurrence or worsening of cardiovascular disease has become a common practice in recent years (Medical ...
Taking aspirin to prevent recurrence or worsening of cardiovascular disease has become a common practice in recent years (Medical Letter, 28:31, 1986). Now, the US Food and Drug Administration is considering whether aspirin can also be advertised for prevention of a first myocardial infarction in previously healthy people.
Med Lett Drugs Ther. 1989 Aug 25;31(799):77-8 |  Show IntroductionHide Introduction

Ramucirumab (Cyramza) for Gastric and GEJ Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • May 11, 2015  (Issue 1468)
thromboembolic events, and gastrointestinal perforation, and can impair wound healing. New onset or worsening ...
Ramucirumab (Cyramza – Lilly), a monoclonal antibody that inhibits vascular endothelial growth factor receptor 2 (VEGFR2), has been approved by the FDA for use as monotherapy or in combination with paclitaxel for treatment of advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after platinum- or fluoropyrimidine-based chemotherapy. Ramucirumab is also approved for use in combination with docetaxel (Taxotere, and others) for treatment of metastatic non-small cell lung cancer that has progressed on or after platinum-based...
Med Lett Drugs Ther. 2015 May 11;57(1468):74-5 |  Show IntroductionHide Introduction

Transdermal Fentanyl (Ionsys) for Postoperative Pain

   
The Medical Letter on Drugs and Therapeutics • Nov 09, 2015  (Issue 1481)
disorders, or bradyarrhythmias should be monitored for worsening symptoms. 156 The Medical Letter ® Vol ...
A patient-controlled fentanyl iontophoretic transdermal system (Ionsys – The Medicines Company) is now available for short-term management of acute postoperative pain in adults requiring opioid analgesia in the hospital. Before using Ionsys, patients must be titrated to a comfortable level of analgesia with another opioid formulation.
Med Lett Drugs Ther. 2015 Nov 9;57(1481):155-6 |  Show IntroductionHide Introduction